BAYER'S STOCK VALUE CONTINUES TO SAG FROM GLYPHOSATE JURY RULINGS
May 15, 2019
Wall Street Journal reports:
Bayer AG shares resumed their months long fall on Tuesday after the company was hit by a more-than $2 billion jury award over its Roundup herbicide, marking a sharp escalation in the chemical and drug giant's legal woes.
The shares were down 2.3% in Europe -- one of the worst performers in the Frankfurt stock exchange's blue-chip DAX index, which was trading up on the day -- after hitting a seven-year low. The fall followed Bayer's third Roundup court defeat in 10 months. A California jury on Monday awarded $2.055 billion to a couple who blamed the weedkiller for causing their cancer, a significantly higher amount than the two-digit million figures Bayer is facing in previous cases.
The verdict overshadowed the first positive news from Bayer in weeks. On Monday, the company said it had reached an agreement to sell its Coppertone sunscreens for $550 million, the first of a series of emergency restructuring measures it planned late last year in an effort to convince increasingly skeptical investors that it has its drugs-to-crops business under control.
Without a court win so far, Bayer has been stuck in a downward spiral, with each new verdict against it pushing its stock lower as shareholders struggled to compute the total scale of the company's potential liabilities surrounding Roundup.
"Sentiment is stuck in the mud," said Citi analyst Peter Verdult, who is now pinning his hopes on the next Roundup trial in St. Louis, which will be the first to take place outside the San Francisco Bay Area, often seen as an unfavorable setting for corporate defendants.
"A positive development of the group's business probably won't have an effect on valuation in the short term," analysts from DZ Bank wrote.
Bayer is appealing all verdicts. The company argues Roundup and its active ingredient glyphosate are safe to use. It hopes to win on appeal, where judges will look over the cases.
After the first verdict, Bayer obtained a substantial reduction in the amount of the award and analysts were optimistic Tuesday that this week's $2 billion award would be reduced too.
Gunther Zechmann from Bernstein research said he expected Monday's award, which included $2 billion in punitive damages, to conclude at $110 million.
Still, the amount granted by the jury this week could make the 13,400 total plaintiffs that Bayer still faces more hesitant to reach a settlement "given the prize available through winning their case," Mr. Zechmann said.
Some investors would like to see Bayer settle sooner rather than later to get clarity over the future of the company.